Endo Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Endo Pharmaceuticals Holdings Inc. (ENDP)

Q4 2011 Earnings Call

February 24, 2012 8:30 am ET

Executives

David Holveck – President, Chief Executive Officer

Alan Levin – Executive Vice President, Chief Financial Officer

Julie McHugh – Chief Operating Officer

Dr. Ivan Gergel – Chief Scientific Officer

Blaine Davis – Vice President, Corporate Affairs

Analysts

Gregg Gilbert – Bank of America Merrill Lynch

John Boris – Citigroup

Shibani Malhotra – RBC Capital Markets

Corey Davis – Jefferies

David Ansellem – Piper Jaffray

Ken Cacciatore – Cowen & Co.

Chris Schott – JP Morgan

Annabel Samimy – Stifel Nicolaus

Jim Dawson – Buckingham Research

Michael Tong – Wells Fargo

Gary Nachman – Susquehanna Financial Group

Presentation

Operator

Compare to:
Previous Statements by ENDP
» Endo Pharmaceuticals at 2011 Credit Suisse Annual Health Care Conference Call Transcript
» Endo Pharmaceuticals Holdings' CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Endo Pharmaceuticals Holdings CEO Discusses Q2 2011 Results - Earnings Call Transcript

Good day ladies and gentlemen and welcome to the Fourth Quarter 2011 Endo Pharmaceuticals Holdings Inc. Earnings conference call. My name is Lacey and I’ll be your coordinator for today. At this time, all participants are in listen-only mode. We will facilitate a question and answer session towards the end of the presentation. If at any time during the call you require assistance, please press star followed by zero and a coordinator will be happy to assist you. As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the presentation over to your host for today’s call, Mr. Blaine Davis, Vice President of Corporate Affairs. Please proceed.

Blaine Davis

Great, thanks Lacey. Good morning everybody and thank you for joining us. With me on this morning’s call are Dave Holveck, President and CEO of Endo; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer, and Alan Levin, Chief Financial Officer. After our prepared remarks, we’ll open the call to your questions.

1 2 3 Next › Last »